21
Participants
Start Date
September 15, 2011
Primary Completion Date
September 15, 2023
Study Completion Date
September 11, 2024
Anti-Thymocyte Globulin
Given IV
Autologous Hematopoietic Stem Cell Transplantation
Undergo autologous PBSCT
Cyclophosphamide
Given IV
Filgrastim
Given SC
Laboratory Biomarker Analysis
Correlative studies
Mycophenolate Mofetil
Given PO
Peripheral Blood Stem Cell Transplantation
Undergo autologous PBSCT
Plerixafor
Given SC
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Duke University Medical Center, Durham
University of Michigan Comprehensive Cancer Center, Ann Arbor
M D Anderson Cancer Center, Houston
The University of Texas Health Science Center, Houston, Houston
Colorado Blood Cancer Institute, Denver
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
City of Hope Comprehensive Cancer Center, Duarte
Seattle Children's Hospital, Seattle
Fred Hutch/University of Washington Cancer Consortium, Seattle
University of Colorado, Denver
Boston Medical Center, Boston
Boston University School of Medicine, Boston
National Cancer Institute (NCI)
NIH
Fred Hutchinson Cancer Center
OTHER